Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
NCT04327661 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 366
Last updated 2024-12-11
Summary
A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in subjects affected by motion sickness during travel
Conditions
Interventions
- DRUG
-
Oral Capsule
- DRUG
-
Oral Capsule
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-11-15
- Primary Completion
- 2023-04-01
- Completion
- 2023-04-12
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Double-blind Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness
NCT01198106 ·Status: UNKNOWN ·Phase: NA
-
The Prevention and Treatment of Nausea Associated With Motion Sickness
NCT03986905 ·Status: COMPLETED ·Phase: PHASE3
-
Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness
NCT04184115 ·Status: COMPLETED ·Phase: PHASE3
-
Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness
NCT04272255 ·Status: UNKNOWN ·Phase: PHASE3
-
Levo Phencynonate Hydrochloride for the Prevention of Seasickness
NCT02241629 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
NCT05548270 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray
NCT02155309 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Galvanic Vestibular Stimulation as a Novel Treatment for Seasickness
NCT05004818 ·Status: COMPLETED ·Phase: NA
-
Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels
NCT03920644 ·Status: UNKNOWN ·Phase: PHASE3
-
A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.
NCT02839135 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Evaluation of the Use of Ginger Extract in the Management of Motion Sickness
NCT03755596 ·Status: COMPLETED ·Phase: PHASE4
-
Treating Benign Paroxysmal Positional Vertigo (BPPV) in ED Patients
NCT00641797 ·Status: COMPLETED ·Phase: NA
-
PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor
NCT06014385 ·Status: WITHDRAWN ·Phase: PHASE1
-
The Efficacy of B6 and Metoclopramide Combination in Comparison With the Other Antiemetics
NCT06390787 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
NCT04947423 ·Status: COMPLETED ·Phase: PHASE3
-
Nebulizer Delivery of Intranasal Scopolamine
NCT04999449 ·Status: COMPLETED ·Phase: PHASE1
-
DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness
NCT04219982 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
NCT05886660 ·Status: RECRUITING ·Phase: PHASE2
-
Visual Distraction as a Means of Enhancing Child Resistance
NCT01859780 ·Status: COMPLETED ·Phase: NA
-
The Effects of Ondansetron on Brain Function
NCT02460341 ·Status: COMPLETED ·Phase: PHASE1
-
Meclizine Plasma Levels in Responders and Non-responders
NCT04482985 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of Methylnaltrexone on GI Transit in Healthy Volunteers
NCT01055704 ·Status: COMPLETED ·Phase: PHASE4
-
Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)
NCT02337842 ·Status: WITHDRAWN ·Phase: PHASE1
-
Testing the Epley Maneuver for Treating Dizziness in the Emergency Department
NCT07111000 ·Status: RECRUITING ·Phase: NA
-
Effects of Tolterodine, a Non-Specific Muscarinic Antagonist, on Gastrointestinal Transit in Healthy Subjects
NCT00332137 ·Status: COMPLETED ·Phase: PHASE2